No abstract

No abstract

reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S259-S274 S267Objectives. To compare patient outcomes and primary tumor behaviours in patients with SCLC that received radiation treatment in tumor primary site and chemotherapy and other group did not and only received systemic treatment (antineoplastic chemotherapy). Patients and methods. This is a retrospective cohort study between April 2007 and December 2011, with a minimum follow up of 12 months. 37 consecutive patients diagnosed with SCLC were treated in our Radiation Oncology Unit in this period. 19 patients received only loco-regional treatment, that include primary tumor and lymph node drainage. Prophylactic cranial irradiation like single treatment was given to 15 patients and only three both treatment modalities (loco-regional lung irradiation plus PCI). Results. Survival rates in patients that primary tumor were treated had a mean survival of 19 months and in no primary treated group had 13 months, a mean difference of 6 months Confidence Interval 95% (0.26-11.74) and p = 0.041. Cumulative incidence of distant metastasis in group with treatment of primary tumor was 0.578; CI 95% (0.36-0.76) and 0.88; CI 95% (0.67-0.96) in arm without this option the difference, p < 0.03. Relative Risk 1.53 CI 95% (1.01-2.32) and Relative Risk Reduction −0.53 CI 95% (−1.33; −0.01) and NNT = −3. Finally, cumulative incidence of local recurrence in primary treatment group was 0.26; 26% and 0.44; 44% in no primary treatment group, showing a p = 0.25. Almost, it shows an Absolute Risk Reduction of −0.18 CI 95% (−0.44, +0.11), NNT −6 CI 95% (−2, +8), Relative Risk 1.68 CI 95% (0.67-4.2).Conclusions. There are significant differences about distant metastases incidence and mean survival time in patients that received radiation treatment in primary tumor vs no treatment group.http://dx.To evaluate the safety and efficacy of EGFR TKIs in combination with RT in the treatment of bone metastasis in patients with NSCLC. Methods. We reviewed the data from patients with NSCLC EIV, that received treatment with TKIs (Erlotinib or Gefitinib) and RT for bone metastasis between 2009 and 2012. For clinical response we used the visual analog scale (VAE) to evaluate the pain control, comparing the preRT value with the 3 months postRT value. A complete clinical response(CR) was considered with a VAE of 0-1 after RT, a partial response(PR) if the initial value was the same or if it decreased, and no response if it increased. To evaluate the radiological response a comparison was made before and 3 months postRT by the radiologist. Results. Overall 20 patients were analysed, with a total of 39 localizations receiving RT. RT to a total dose of 8-30 Gy in 1-10 fractions was used. A positive EGFR mutation status was achieved in seven patients, and negative or no information in the rest. Eight concomitant treatments (RT and TKIs) were applied. The RT and TKIs clinical response rate at three months was CR in 75% (6) and a PR in 25% (1). The radiological response was informed stable or PR...

change of motion pattern). Based on these findings, additional modelling functionality was added. Afterward, one additional pt was treated with less pauses (Pre-update:8AE6.2, Post:1.6AE1.5). Another pt was attempted, but difficulty identifying the lesion near the diaphragm led to tx being aborted and gating plan being initiated. Among those with follow up (n Z 4, mean:4 mo, R:1-6 mo), no pts displayed any grade 2 or higher toxicities. Conclusion: We report the first RMSTC for helical tomotherapy delivery in pts. Accuracy and safety of tx delivery was confirmed. Early experience has informed workflow. Appropriate pt selection is evolving, further evaluation is needed for lesions near the diaphragm. Additional study and follow up is warranted and planned.

No abstract